Swedish TV4: Watch how genomics and machine learning are replacing animal testing in chemical safety
SenzaGen joined Lund University researchers on Swedish TV4 to show how genomics- and machine learning-based methods are transforming the field — delivering faster, more accurate, and human-relevant safety assessment.
See how these approaches can protect human health, meet evolving regulatory demands, and open new opportunities in a market driven by scientific innovation and the global shift away from animal testing.
SenzaGen’s Newsletter Q1 2026
Click image to view the Newsletter in browser.
Text version:
SenzaGen Newsletter Q1, 2026
SOT 2026: Advancing NAMs for skin and respiratory sensitization testing
We had a fantastic time at this year’s SOT meeting in San Diego, connecting with peers, exploring new ideas, and sharing the latest GARD® data on skin and respiratory sensitization from our industry collaborations. Thank you to all our collaborative partners for the outstanding teamwork!
Bayer | Coty | ExxonMobil | GDIT | Haleon | J&J MedTech | Merck
GARD for assessing biopesticides and complex mixtures
Dr Andy Forreryd and Dr Tim Lindberg of SenzaGen presented at SOT symposium sessions, demonstrating how GARD® supports sensitization assessment of biopesticides and complex mixtures.
Respiratory sensitization, protein allergy and medical devices
At SenzaGen’s hosted session, guest speakers from Merck, GDIT, and J&J MedTech shared new GARD® data on respiratory sensitization and ISO 10993-10 compliance for medical devices.
New scientific publication: Quantitative risk assessment of fragrance materials using NAMs
The collaborative work within the International Dialogue for the Evaluation of Allergens (IDEA) has been recently published in Regulatory Toxicology and Pharmacology, presenting new peer-reviewed evidence on the application of New Approach Methodologies (NAMs) in quantitative risk assessment (QRA) of fragrance materials.
The study demonstrates that SenzaGen’s single-assay method GARD®skin Dose-Response, alongside the multiple-assay approaches, delivers PoDs that well align with established human and animal reference potency data, within the expected biological variability.
Establishing safe dose levels for cosmetic ingredients
We are pleased to see another leading global cosmetics company adopt GARD®skin Dose-Response to assess safe use levels of ingredients with potential skin-sensitizing properties. Powered by genomics and machine learning, the assay can be used as a standalone method to support robust, science-driven product development.
Explore 3 typical use scenarios
Upcoming events
🌎 Conference: ITCASS and ERGECD meeting | Strasbourg, France | April 15-17
🎧 Webinar: Advancing NAMs for respiratory sensitization testing-SOT Recap | Apr 22
🌎 Conference: ESTIV Congress | Maastricht, the Netherlands | June 29-July 2
New peer-reviewed publication by IDEA working group: Derivation of a Point of Departure using NAMs for application in Quantitative Risk Assessment of fragrance material
Advancing quantitative NAMs for skin sensitization risk assessment – Collaborative work within IDEA QRA-NAMs Working Group
A new article published in Regulatory Toxicology and Pharmacology presents the outcomes of collaborative work within the International Dialogue for the Evaluation of Allergens (IDEA) QRA-NAMs Working Group.
The publication demonstrates how quantitative New Approach Methodologies (NAMs) can be used to derive Points of Departure (PoDs) for skin sensitization risk assessment.
The study provides peer-reviewed evidence that SenzaGen’s single-assay method GARD®skin Dose-Response, alongside the multiple-assay approaches, delivers PoDs that well align with established human and animal reference potency data, within the expected biological variability.
We are proud that SenzaGen expert Dr Andy Forreryd contributed to the scientific discussions and to the development of the GARD®skin dose-response methodology supporting this work.
About the study
Three quantitative NAM approaches were evaluated across 110 fragrance-related chemicals, benchmarked against the extended IDEA Reference Chemical Potency List (RCPL), which integrates human and animal reference data:
- Defined approaches combining multiple assays: Regression model and SARA-ICE.
- GARD®skin Dose-Response: a genomic-based assay evaluated as a stand-alone method.
Scientific and regulatory impact
The work addresses a critical gap in NAM adoption: moving beyond hazard identification to quantitative, decision-relevant risk assessment.
Importantly, the study goes further than method comparison by defining NAM-specific adjustment factors, enabling translation of NAM-PoDs into NESILs for use in Quantitative Risk Assessment (QRA), even for new materials where no legacy data are available. Together, these results provide a scientifically robust and practically applicable framework for implementing quantitative, NAM-based skin sensitization risk assessment and support the continued transition toward animal-free, human-relevant safety assessment.
ndreas Natsch, Peter Griem, Amaia Irizar, James Bridges, Matthias Vey, Isabelle Lee, Anne Marie Api, Petra Kern, Ian Kimber, Derivation of a Point of Departure using NAMs for application in Quantitative Risk Assessment of fragrance materials, Regulatory Toxicology and Pharmacology, Volume 167,2026,106052,ISSN 0273-2300,https://doi.org/10.1016/j.yrtph.2026.106052. https://www.sciencedirect.com/science/article/pii/S0273230026000255
Keywords
Skin sensitization, In vitro testing, Point of departure, Quantitative risk assessment, SARA-ICE, Regression model, GARDskin
Abstract
Skin sensitization is a key endpoint for the safety assessment of topical consumer products. Ingredients with the potential to act as skin sensitizers differ markedly in their threshold for induction but can be used safely if their potency is characterized and exposure remains within an appropriate margin of safety. To this end, the fragrance industry co-developed Quantitative Risk Assessment (QRA) which starts with the No-Expected-Sensitization-Induction-Level (NESIL). Historically, QRA relies on a weight of evidence approach based on animal data, human confirmatory tests and read across. To allow an approach based solely on New Approach Methodologies (NAMs), the International Dialogue for the Evaluation of Allergens (IDEA) initiative, developed an extended Reference Chemical Potency List (RCPL) integrating human and animal data to derive potency values (PV). Here, we use PVs to evaluate the suitability of quantitative NAMs, including Defined Approaches (DAs), to derive a Point-of-Departure (NAM-PoD) for skin sensitization potency assessment. Evaluation of NAM-PoD derived by SARA-ICE DA, Regression DA and GARDskin dose-response assay (GSDR), indicates that the sensitization potency of fragrance chemicals can be reliably predicted using each approach. Through comparison of NAM-PoDs with in vivo human sensitization thresholds, NAM-specific adjustment factors were derived to convert NAM-PoDs into NAM-NESILs for QRA.
SenzaGen’s Newsletter Q4 2025
Click image to view the Newsletter in browser.
Text version:
SenzaGen Newsletter Q4, 2025
As 2025 draws to a close: |
||||||||||||||||||||||
This quarter caps a year of significant progress in advancing non-animal sensitization testing and closing critical data gaps. Combing genomics and machine leaning, GARD® continues to deliver solutions for Safe Dose Levels, Medical Devices, and Challenging Chemicals—driving the shift toward reliable, human-relevant approaches.
|
SenzaGen’s Newsletter Q3 2025
Click image to view the Newsletter in browser.
|
|
|
|
|
|
|
|
Joint poster with Urgo: Supporting hypoallergenicity claims for Medical Wound Dressings
Supporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARD®skin Medical Device and Dose-Response protocols.
Presented at 2025 Eurotox
Conclusion
This case study demonstrates how NAMs like GARD® can be effectively integrated into product development for assessing skin sensitization potential in medical device extracts. It enables evidence-based decision-making and supports hypoallergenic claims, without the use of animal testing.
Abstract
Biocompatibility testing is a crucial part of medical device safety assessments both for regulatory acceptance of finished products but also within the developmental pipelines of novel devices. Along with cytotoxicity and irritation, skin sensitization is a key toxicological endpoint that must be assessed for all devices. While testing for the two former endpoints is partly conducted in vitro, traditional animal experimentations for skin sensitization testing are still routinely conducted. Thus, validation and implementation of New Approach Methods (NAMs) remains a prioritized goal of the medical device industry.
The GARDskin method (OECD 442E) is a NAM for hazard assessment of skin sensitizers based on test chemical exposure of dendritic cell-like cells followed by a genomic readout. Several method adaptations have been proposed in order to address specific needs of various industry segments. Such adaptations include the GARDskin Dose-Response (DR) method, which facilitates quantitative assessment of sensitizing potency, and the GARDskin Medical Device (MD) method, which facilitates testing of solid materials in accordance with ISO 10993 standards.
Here we report an experimental setup combining the protocols of above-mentioned GARDskin adaptations used to evaluate the relative hypoallergenicity of two sensitive skin dressings: a candidate product and a marketed comparative product. The extraction from the solid test items was performed according to ISO 10993-12, but with an increased test item to extraction vehicle ratio of 6x. The oversaturated extracts were subsequently subjected to serial dilution facilitating dose-response testing in order to evaluate, assess and compare the test items’ relative skin sensitizing potentials.
The results concluded that both test items were classified as non-sensitizers. Due to the oversaturation extraction procedure, otherwise adhering to the ISO 10993-12 standards, the results are noteworthy. Indeed, due to the manyfold increase in material to vehicle ratio, labelling the tested skin dressings as hypoallergenic, or otherwise suitable for sensitive use, may be supported by the data. Furthermore, evaluation of the relative difference between the two test items concluded that the comparative test item induced elevated response values at the highest tested concentration, whereas the candidate test item did not. As such, it could be argued that the candidate product can be claimed as hypoallergenic similarly to the comparative product.
In summary, this experimental setup combining GARDskin MD and GARDskin DR protocols can successfully be used to support claims of hypoallergenicity of medical devices, as well as comparing candidate products with respect to their relative skin sensitizing potential. These results illustrate how such strategies can be routinely integrated in the development of novel devices giving data for critical decision-making without resorting to animal experimentation for regulatory approval.
Joint poster with BIC: Case study on skin-binding dyes
In vitro skin sensitization potency assessment using GARD®skin Dose-Response: A case study on natural extracts-based skin-binding dyes and dye precursors
Presented at 2025 Eurotox
Conclusion
- GARD® skin Dose-Response provides ready-to-use NESIL values, supporting the establishment of safe dose levels for skin sensitizers.
- The assay is a non-animal alternative for skin sensitization potency testing, enabling potency ranking of candidate products and quantitative risk assessment.
Abstract
Naturally occurring skin dyes and dye precursors are widely used in temporary tattoo products, evolving from unrefined fruit extracts to more refined formulations in various ink applications. Evaluating their skin sensitization potential and establishing safe use levels for potential sensitizers are critical for product safety, which has traditionally relied on animal testing and/or human patch testing. While New Approach Methodologies (NAMs) have been developed to replace in vivo assays, a need remains for methods that can effectively and quantitatively characterize skin sensitizing potency.
GARD®skin (OECD TG 442E) is an in vitro assay that identifies chemical skin sensitizers based on the transcriptional profiling of a 196-gene biomarker signature in the dendritic-like SenzaCell® cell line. Predictions are made using a machine-learning algorithm, which classify test chemicals as sensitizers or non-sensitizers based on the assay’s readout, Decision Values (DVs). GARD®skin Dose-Response (OECD TGP 4.106) extends this approach by evaluating test chemicals across a concentration range to establish a dose-response relationship between DVs and test chemical concentration. Sensitizing potency is quantified using cDV0, the lowest dose required to elicit a positive response in GARD®skin. Depending on the need, the readout can be used to predict LLNA EC3 values, No Observable Effect Levels (NOELs)/No Expected Sensitization Induction Levels (NESILs), Human Potency (HP) Categories, and UN GHS/CLP classification (1A or 1B), all with high statistical significance.
This case study demonstrates the application of GARD®skin Dose-Response to quantitatively assess the skin sensitization potency of naturally occurring dye precursor that binds covalently to skin molecules, highlighting its use in temporary tattoo inks. Seven analogue molecules with different functional groups were investigated. While six exhibited varying degrees of sensitization potency with mean cDV0 values ranging from 3.82 µM to 34.3 µM, one functional group did not induce a positive response at any of the assayed concentrations and was subsequently classified as a non-sensitizer. Predicted LLNA EC3 values ranged from 0.60% to 4.72%, corresponding to Human Potency Categories HP2 to HP4, with NESIL estimates between 258 to 2840 µg/cm².
These findings demonstrate that GARD®skin Dose-Response provides ready-to-use NESIL values, enabling potency ranking of candidate ingredients and supporting the safety assessment of novel dyes and dye precursors. The study further highlights the assay’s value as a non-animal alternative for skin sensitization potency assessment in product development.
